topotecan + vorinostat

Topotecan + vorinostat is an investigational combination therapy consisting of two small molecule drugs with distinct mechanisms of action, evaluated primarily for the treatment of relapsed or recurrent small cell lung cancer (SCLC). Topotecan is a topoisomerase I inhibitor that induces DNA damage by stabilizing the topoisomerase I-DNA complex, leading to replication arrest and apoptosis. Vorinostat is a histone deacetylase (HDAC) inhibitor that modulates gene expression and promotes cell cycle arrest and apoptosis. Preclinical studies have demonstrated strong synergistic antitumor effects when these agents are combined, resulting in enhanced S-phase cell cycle arrest, increased DNA double-strand breaks, and caspase-dependent apoptosis. The combination has been explored in early-phase clinical trials for chemosensitive recurrent SCLC[1][2][5].

Other names

vorinostat and topotecantopotecan and vorinostat